Sandoz Group（SDZ）株式概要
サンドグループAGは、ジェネリック医薬品およびバイオシミラーの開発、製造、販売を世界中で行っている。 詳細
SDZ Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sandoz Group AG 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | CHF 64.40 |
| 52週高値 | CHF 72.70 |
| 52週安値 | CHF 42.01 |
| ベータ | 0.53 |
| 1ヶ月の変化 | -3.71% |
| 3ヶ月変化 | 1.55% |
| 1年変化 | 46.30% |
| 3年間の変化 | n/a |
| 5年間の変化 | n/a |
| IPOからの変化 | 164.48% |
最新ニュース
ナラティブの更新 • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.ナラティブの更新 • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.
ナラティブの更新 • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
ナラティブの更新 • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Recent updates
ナラティブの更新 • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.ナラティブの更新 • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.ナラティブの更新 • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.ナラティブの更新 • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.ナラティブの更新 • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.ナラティブの更新 • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.ナラティブの更新 • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.ナラティブの更新 • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.ナラティブの更新 • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.ナラティブの更新 • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.ナラティブの更新 • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.ナラティブの更新 • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.ナラティブの更新 • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.ナラティブの更新 • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.ナラティブの更新 • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.ナラティブの更新 • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.新しいナラティブ • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.分析記事 • Jun 25
Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)
You may think that with a price-to-sales (or "P/S") ratio of 2.2x Sandoz Group AG ( VTX:SDZ ) is definitely a stock...株主還元
| SDZ | CH Pharmaceuticals | CH 市場 | |
|---|---|---|---|
| 7D | 0.3% | 2.7% | 0.4% |
| 1Y | 46.3% | 23.8% | 6.6% |
業界別リターン: SDZ過去 1 年間で23.8 % の収益を上げたSwiss Pharmaceuticals業界を上回りました。
リターン対市場: SDZ過去 1 年間で6.6 % の収益を上げたSwiss市場を上回りました。
価格変動
| SDZ volatility | |
|---|---|
| SDZ Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.4% |
安定した株価: SDZ 、 Swiss市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: SDZの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1886 | 22,356 | Richard Saynor | www.sandoz.com |
サンドグループAGは、ジェネリック医薬品およびバイオシミラーの開発、製造、販売を世界中で行っている。同社は、循環器、中枢神経、腫瘍、感染症、疼痛・呼吸器、糖尿病、免疫、内分泌、血液、眼科などの治療領域をカバーしている。また、原薬や最終製剤のポートフォリオも提供している。同社は1886年に設立され、スイスのバーゼルに本社を置いている。
Sandoz Group AG 基礎のまとめ
| SDZ 基礎統計学 | |
|---|---|
| 時価総額 | CHF 27.87b |
| 収益（TTM） | CHF 727.59m |
| 売上高(TTM) | CHF 8.88b |
38.3x
PER（株価収益率3.1x
P/SレシオSDZ は割高か？
公正価値と評価分析を参照収益と収入
| SDZ 損益計算書（TTM） | |
|---|---|
| 収益 | US$11.16b |
| 売上原価 | US$5.86b |
| 売上総利益 | US$5.30b |
| その他の費用 | US$4.39b |
| 収益 | US$914.00m |
直近の収益報告
Dec 31, 2025
次回決算日
Aug 05, 2026
| 一株当たり利益（EPS） | 2.11 |
| グロス・マージン | 47.50% |
| 純利益率 | 8.19% |
| 有利子負債／自己資本比率 | 56.6% |
SDZ の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
1.2%
現在の配当利回り48%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/08 09:41 |
| 終値 | 2026/06/05 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Sandoz Group AG 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。36
| アナリスト | 機関 |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |